Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
MEGF6 Biologics Sequence Review Report 2026: Multiple epidermal growth factor-like domains protein 6 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MEGF6 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
MEGF10 Biologics Sequence Review Report 2026: Multiple epidermal growth factor-like domains protein 10 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MEGF10 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
MCHR2 Biologics Sequence Review Report 2026: Melanin-concentrating hormone receptor 2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MCHR2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
MCHR1 Biologics Sequence Review Report 2026: Melanin-concentrating hormone receptor 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MCHR1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
MARCO Biologics Sequence Review Report 2026: Macrophage receptor MARCO Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MARCO sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
MAGEE1 Biologics Sequence Review Report 2026: Melanoma-associated antigen E1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGEE1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
MAGED4 Biologics Sequence Review Report 2026: Melanoma-associated antigen D4 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGED4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
MAGED2 Biologics Sequence Review Report 2026: Melanoma-associated antigen D2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGED2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
MAGED1 Biologics Sequence Review Report 2026: Melanoma-associated antigen D1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGED1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
MAGEC3 Biologics Sequence Review Report 2026: Melanoma-associated antigen C3 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGEC3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
MAGEC2 Biologics Sequence Review Report 2026: Melanoma-associated antigen C2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGEC2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
MAGEB6 Biologics Sequence Review Report 2026: Melanoma-associated antigen B6 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGEB6 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.